Skip to main content

Table 1 Demographics and treatment history of the STS PDX donor patients

From: Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts

PDX model Gender Age range at diagnosis (years) STS subtype Primary tumor location Metastatic disease at time of engraftment Metastatic disease after engraftment Treatment response (after xenografting)
UZLX-STS22 Male 50–60 Leiomyosarcoma Quadriceps muscle No Yes PD under doxorubicin + evofosfamide
PD under trabectedin
UZLX-STS39 Female 60–70 Malignant peripheral nerve sheath tumor Abdominal wall No Yes Refusal of chemotherapy
UZLX-STS59 Male 50–60 Myxofibrosarcoma Adductor muscle Yes Yes PD under doxorubicin
PD under ifosfamide
PD under pazopanib
PD under trabectedin
UZLX-STS84 Female 70–80 Undifferentiated pleomorphic sarcoma Adductor muscle No Yes PD under pazopanib
  1. PD progressive disease, PDX patient-derived xenograft, STS soft tissue sarcoma